Eisai/Biogen Maintain Lead Over Lilly In New Race To Alzheimer’s Approval
Full Approval Filing May Quickly Follow Accelerated US FDA Decision
The US FDA accepted an application for accelerated approval and set a 6 January action date, giving lecanemab ample time to reach the market ahead of Lilly’s competing anti-amyloid antibody donanemab.
